Bill would limit gifts, allow sampling
Bill would limit gifts,allow sampling
Representative Pete Stark (D-CA) has introduced the "Save Money for Prescription Drug Research Act of 2000," a bill that would deny tax deductions for certain gifts provided to physicians by drug manufacturers. If passed, the bill would not apply to samples.
Stark accused the pharmaceutical industry of spending twice as much money on marketing and administration as it does on research and development and called gifts to doctors "bribes." "Rather than spending pharmaceutical dollars on these very questionable gifts, the industry should devote the billions of dollars on life-saving drugs," Stark said in an introductory speech.
The bill would apply to all gifts "provided directly or indirectly to or for the benefit of a physician, including gifts of meals, sponsored teachings, symposia and travel."
"The need for this bill is clear," Stark said. "Denying the pharmaceutical industry the ability to deduct expenditures for gifts (other than product samples) to physicians is a critical step in providing Americans with access to more life-saving drugs. This will discourage drug company gifts that have been shown to sway physician prescribing behavior and free up more pharmaceutical revenue for R&D. By redirecting drug company promotional expenditures to their R&D budgets, the American public would reap the benefit of increased medical breakthroughs." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.